Noopept vs Teduglutide
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
NoopeptRecovery & Repair
Teduglutide- Summary
- Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
- Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
- Half-Life
- ~5–10 minutes but metabolite (CPG) effects last hours
- ~2 hours; once-daily dosing due to gut-specific residence
- Admin Route
- Oral, Sublingual, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 10–30 mg
- 0.05 mg/kg/day
- Frequency
- 1–2x daily
- Once daily
- Key Benefits
- Enhances memory formation and recall
- Improves learning speed and cognitive processing
- Neuroprotective via BDNF/NGF upregulation
- Anxiolytic at low-to-moderate doses
- Improves verbal fluency and information processing
- Antioxidant (reduces oxidative damage in neurons)
- May improve cognitive symptoms of mild cognitive impairment
- Increases intestinal villus height and absorption surface area
- Reduces intestinal permeability (leaky gut)
- FDA-approved for short bowel syndrome
- Reduces parenteral nutrition dependence in SBS patients
- Promotes intestinal mucosal healing in IBD
- Increases tight junction proteins ZO-1 and occludin
- Side Effects
- Headaches (choline depletion — pair with choline source)
- Irritability or anxiety at high doses
- Overstimulation
- Rare: brain fog with chronic use
- +1 more
- Injection site reactions
- Abdominal pain and bloating
- Nausea
- Risk of intestinal polyp growth (requires colonoscopy surveillance)
- +1 more
- Stacks With
- —
- —